GB2479153A — Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy
Assigned to GW Pharma Ltd · Expires 2011-10-05 · 15y expired
What this patent protects
The invention relates to the use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy, in particular epilepsy characterised by generalised seizures. CBDV may be used in an isolated form or as a botanical drug substance. Preferably, CBDV is used with one or m…
USPTO Abstract
The invention relates to the use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy, in particular epilepsy characterised by generalised seizures. CBDV may be used in an isolated form or as a botanical drug substance. Preferably, CBDV is used with one or more therapeutically effective phytocannabinoids such as tetrahydrocannabivarin (THCV) and cannabidiol (CBD), and in combination with a standard anti-epileptic drug, Also claimed is a cannabis plant extract for use in the treatment of epilepsy, the extract containing at least 50 wt% of a phytocannabinoid fraction including CBDV as principal phytocannabinoid and CBD as secondary phytocannabinoid, and a non-phytocannabinoid fraction including monoterpenes and sesquitelpenes. Preferably the cannabis plant extract further comprises THCV. Some of the examples relate only to the use of THCV or CBD in models of epilepsy.
Drugs covered by this patent
- Epidiolex (CANNABIDIOL) · Jazz Pharms Res
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.